JP4721488B2 - 腎細胞ガン処置 - Google Patents

腎細胞ガン処置 Download PDF

Info

Publication number
JP4721488B2
JP4721488B2 JP2000105531A JP2000105531A JP4721488B2 JP 4721488 B2 JP4721488 B2 JP 4721488B2 JP 2000105531 A JP2000105531 A JP 2000105531A JP 2000105531 A JP2000105531 A JP 2000105531A JP 4721488 B2 JP4721488 B2 JP 4721488B2
Authority
JP
Japan
Prior art keywords
composition
pegylated interferon
patient
interferon alpha
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000105531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001288110A5 (https=
JP2001288110A (ja
JP2001288110A6 (ja
Inventor
ヘレン ローズ エザー
エレン ライバク メアリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2001288110A publication Critical patent/JP2001288110A/ja
Publication of JP2001288110A6 publication Critical patent/JP2001288110A6/ja
Publication of JP2001288110A5 publication Critical patent/JP2001288110A5/ja
Application granted granted Critical
Publication of JP4721488B2 publication Critical patent/JP4721488B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2000105531A 1999-04-08 2000-04-06 腎細胞ガン処置 Expired - Fee Related JP4721488B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08
US09/288,359 1999-04-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000105528A Division JP3712914B2 (ja) 1999-04-08 2000-04-06 腎細胞ガン処置

Publications (4)

Publication Number Publication Date
JP2001288110A JP2001288110A (ja) 2001-10-16
JP2001288110A6 JP2001288110A6 (ja) 2006-12-07
JP2001288110A5 JP2001288110A5 (https=) 2007-05-31
JP4721488B2 true JP4721488B2 (ja) 2011-07-13

Family

ID=23106761

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000105531A Expired - Fee Related JP4721488B2 (ja) 1999-04-08 2000-04-06 腎細胞ガン処置
JP2000105528A Expired - Fee Related JP3712914B2 (ja) 1999-04-08 2000-04-06 腎細胞ガン処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2000105528A Expired - Fee Related JP3712914B2 (ja) 1999-04-08 2000-04-06 腎細胞ガン処置

Country Status (23)

Country Link
EP (2) EP1043025B1 (https=)
JP (2) JP4721488B2 (https=)
CN (1) CN1367702A (https=)
AR (1) AR029160A1 (https=)
AT (2) ATE419002T1 (https=)
AU (2) AU777406B2 (https=)
BR (1) BR0009644A (https=)
CA (1) CA2303752A1 (https=)
CO (1) CO5170412A1 (https=)
CY (1) CY1108919T1 (https=)
DE (2) DE60041291D1 (https=)
DK (2) DK1043025T3 (https=)
ES (2) ES2239953T3 (https=)
HU (1) HU230271B1 (https=)
MX (1) MXPA00003401A (https=)
MY (1) MY155221A (https=)
NO (1) NO328983B1 (https=)
NZ (1) NZ514629A (https=)
PE (1) PE20010026A1 (https=)
PT (2) PT1535623E (https=)
TW (2) TW200526243A (https=)
WO (1) WO2000061174A2 (https=)
ZA (1) ZA200108169B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1043025B1 (en) * 1999-04-08 2005-06-01 Schering Corporation Renal cell carcinoma treatment
WO2007126950A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
DK2552443T3 (da) 2010-04-01 2021-09-27 Oncorena Ab Forbedret behandling af nyrecellekarcinom
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2024186735A1 (en) * 2023-03-03 2024-09-12 Memorial Sloan-Kettering Cancer Center Methods and compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO1999048535A1 (en) * 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
EP1043025B1 (en) * 1999-04-08 2005-06-01 Schering Corporation Renal cell carcinoma treatment

Also Published As

Publication number Publication date
NO328983B1 (no) 2010-07-05
PE20010026A1 (es) 2001-02-05
EP1535623B1 (en) 2008-12-31
JP2000319196A (ja) 2000-11-21
DE60020442T2 (de) 2006-05-04
HUP0200781A3 (en) 2002-09-30
NZ514629A (en) 2004-02-27
AU4204400A (en) 2000-11-14
EP1535623A1 (en) 2005-06-01
BR0009644A (pt) 2002-01-08
ZA200108169B (en) 2003-01-06
ATE419002T1 (de) 2009-01-15
EP1043025A2 (en) 2000-10-11
WO2000061174A2 (en) 2000-10-19
EP1043025B1 (en) 2005-06-01
HK1075417A1 (en) 2005-12-16
CA2303752A1 (en) 2000-10-08
AU2004242454A1 (en) 2005-01-20
ES2319777T3 (es) 2009-05-12
HUP0200781A2 (en) 2002-08-28
CN1367702A (zh) 2002-09-04
JP2001288110A (ja) 2001-10-16
DK1535623T3 (da) 2009-04-27
AU777406B2 (en) 2004-10-14
DE60020442D1 (de) 2005-07-07
AU2004242454B2 (en) 2007-02-15
HU230271B1 (hu) 2015-11-30
MY155221A (en) 2015-09-30
EP1043025A3 (en) 2000-12-20
DE60041291D1 (de) 2009-02-12
DK1043025T3 (da) 2005-07-04
ATE296638T1 (de) 2005-06-15
CY1108919T1 (el) 2014-07-02
HK1032533A1 (en) 2001-07-27
PT1535623E (pt) 2009-03-19
NO20014851D0 (no) 2001-10-05
PT1043025E (pt) 2005-09-30
ES2239953T3 (es) 2005-10-16
MXPA00003401A (es) 2002-03-08
CO5170412A1 (es) 2002-06-27
JP3712914B2 (ja) 2005-11-02
WO2000061174A3 (en) 2001-01-25
AR029160A1 (es) 2003-06-18
TW200526243A (en) 2005-08-16
NO20014851L (no) 2001-12-07
TWI310314B (en) 2009-06-01

Similar Documents

Publication Publication Date Title
US7482014B2 (en) Melanoma therapy
JP4721488B2 (ja) 腎細胞ガン処置
US6362162B1 (en) CML Therapy
JP2001288110A6 (ja) 腎細胞ガン処置
US6605273B2 (en) Renal cell carcinoma treatment
AU2004242456B2 (en) CML therapy
HK1032533B (en) Renal cell carcinoma treatment
HK1075417B (en) Renal cell carcinoma treatment
JP2000319195A (ja) 黒色腫治療
JP2001288109A (ja) 黒色腫治療
JP2001288109A6 (ja) 黒色腫治療
HK1032348B (en) Chronic myeloid leukemia (cml) therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101220

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20110224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110329

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110405

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140415

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees